Skip to main content
Gubra A/S logo

Gubra A/S — Investor Relations & Filings

Ticker · GUBRA ISIN · DK0062266474 LEI · 254900T17RRFZONO6W53 CO Professional, scientific and technical activities
Open in API
Filings indexed 87 across all filing types
Latest filing 2023-08-25 Interim / Quarterly Rep…
Country DK Denmark
Listing CO GUBRA

About Gubra A/S

https://www.gubra.dk/

Gubra A/S is a biotechnology company and preclinical Contract Research Organization (CRO) specializing in peptide-based drug discovery. The company operates a dual business model, providing preclinical research services to pharmaceutical and biotech clients while also developing its own proprietary pipeline of therapeutics. Gubra's primary focus is on metabolic diseases, such as obesity, diabetes, and MASH (metabolic dysfunction-associated steatohepatitis), as well as fibrotic diseases. Its research and development activities also extend into inflammatory conditions, CNS, respiratory, and women's health. The CRO services division supports clients in advancing their drug development programs through expertise in areas like in vivo pharmacology and peptide chemistry.

Recent filings

Filing Released Lang Actions
Interim report H1-2023: Strong performance and ahead of expectations
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Interim report H1-2023' and contains detailed financial tables, including revenue, EBIT, and adjusted EBIT-margin for both the CRO and D&P segments, as well as a revised outlook for 2023. While it is formatted as a regulatory press release, it provides substantive financial data and analysis for the first half of the fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-25 English
Interim report H1-2023: Strong performance and ahead of expectations
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Financial Report' for the first half-year (H1) of 2023. It contains comprehensive financial statements, including consolidated statements of income, balance sheets, cash flow statements, and notes, as well as a detailed management review. It is not an announcement of a report (RPA) because it contains the full financial data and analysis. It is not a 10-K as it covers an interim period (H1) rather than a full fiscal year. Therefore, it is classified as an Interim/Quarterly Report. H1 2023
2023-08-25 English
Gubra announces termination of collaboration with Bayer
Regulatory Filings Classification · 95% confidence The document is a regulatory press release announcing the termination of a specific business collaboration (the cardio-renal peptide programme) between Gubra and Bayer. It does not fit into specific categories like M&A (which usually involves corporate takeovers or mergers), nor is it a financial report or a dividend announcement. As it is a general regulatory announcement regarding business operations and partnership status, it falls under the RNS (Regulatory Filings) category.
2023-08-23 English
Gubra A/S announces signing of collaboration agreement with Hemab ApS
Regulatory Filings Classification · 95% confidence The document is a regulatory press release announcing a new business collaboration agreement between Gubra A/S and Hemab ApS. It details the nature of the partnership, the financial implications (a single-digit DKK million payment), and the strategic intent. Since this is a general corporate announcement regarding business operations and partnerships that does not fit into specific categories like M&A (which usually implies a takeover or merger) or financial reporting, it falls under the general regulatory announcement category.
2023-08-21 English
Gubra raises financial guidance for full-year 2023
Earnings Release Classification · 100% confidence The document is a regulatory press release announcing an upward revision of financial guidance for the full-year 2023. It provides preliminary revenue figures and highlights key performance drivers. It explicitly states that the full half-year report will be published at a later date (25 August 2023). Since this is an initial announcement of financial results and guidance updates rather than the full report itself, it falls under the Earnings Release category. H1 2023
2023-08-15 English
Information on share buy-back programme
Transaction in Own Shares Classification · 100% confidence The document is a regulatory press release announcing the details of a share buy-back programme, specifically reporting the number of shares repurchased and the company's total treasury share holdings. This falls directly under the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2023-07-28 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.